MedTrace Logo

Multi-Center Molecular Diagnosis and Host Response of Respiratory Viral Infections in Pediatric Transplant Recipients

NCT05550298 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 2000

Last updated 2025-10-02

No results posted yet for this study

Summary

The participants are being asked to take part in this clinical trial, a type of research study, because the participants are scheduled to receive or have recently received a hematopoietic cell transplant (HCT) or a solid organ transplant (SOT).

Primary Objective

To determine if pre-transplant screening for respiratory viral load predicts RVI within 1- year post-transplant among survivors.

Secondary Objectives:

* To develop and validate a classifier based on pre-transplant immunological profile predictive of developing an acute respiratory viral infection (aRVI), with RSV/PIV3/HMPV/SARS-CoV-2 through one-year post-transplant among survivors.
* To develop and validate a classifier based on Day +100 post-transplant immunological profiles predictive of developing an acute respiratory viral infection (aRVI),with RSV/PIV3/HMPV/SARS-CoV-2 through one-year post-transplant among survivors .

Conditions

  • Hematopoietic Cell Transplant
  • Solid Organ Transplant
  • Respiratory Viral Infection

Sponsors & Collaborators

  • St. Jude Children's Research Hospital

    collaborator OTHER

  • Seattle Children's Hospital

    collaborator OTHER

  • The Children's Hospital at Montefiore

    collaborator OTHER

  • National Institute of Allergy and Infectious Diseases (NIAID)

    collaborator NIH

  • Arkansas Children's Hospital Research Institute

    lead OTHER

Principal Investigators

  • Gabriela Maron, MD · St. Jude Children's Research Hospital

  • William J. Steinbach, MD · Arkansas Children's Hospital Research Institute

Eligibility

Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-13
Primary Completion
2027-08-31
Completion
2029-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05550298 on ClinicalTrials.gov